Q2 2026 CVRx Inc Earnings Call Transcript
Key Points
- CVRx Inc (CVRX) delivered total revenue of $15.7 million in Q2 2026, a 16% increase year-over-year, with gross margin expanding to 87%.
- The company's strategy is validated by strong double-digit growth in regions with stable, seasoned leadership and limited turnover.
- Reimbursement is improving, with overall 30-day Medicare Advantage prior authorization approval rates rising to 60% in Q2 from 44% in 2025, and Humana's coverage policy driving approval rates above 90%.
- Traditional Medicare claims for the Barostim procedure are now being paid at approximately 96% across all seven Medicare administrative contractors, and CMS has increased the inpatient payment rate to $45,000.
- The BENEFIT-HF trial is tracking ahead of internal expectations on both center activations and patient enrollment, and the company is investing in real-world evidence that could potentially support an expanded indication.
- The company is taking decisive action to fix sales execution issues by investing in onboarding, training, and new field-based roles, funded through reallocation of resources and lower operating expense guidance.
- CVRx Inc (CVRX) lowered its full-year 2026 revenue guidance to between $58 and $60 million due to weaker-than-expected back-half performance.
- Sales force productivity is challenged by high turnover, with roughly 60% of quota-carrying territory managers having joined in the last 18 months, straining onboarding and training processes.
- The company's largest Medicare Advantage payer implemented AI-based prior authorization tools, causing its 30-day approval rate to fall sharply to below 30%, making physicians hesitant to recommend Barostim.
- The company is not anticipating adding any new sales territories for the balance of the year, which will likely limit net growth in active implanting centers.
- Revenue in Europe decreased by 31% year-over-year, with total revenue units dropping to 40 from 61 in the prior year period.
- CVRx Inc (CVRX) received a civil investigative demand from the US Department of Justice in May 2026 related to certain sales and marketing practices, and the company is fully cooperating with the investigation.
Greetings and welcome to the CVRX Second Quarter 2026 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Mike Vallee, with ICR Healthcare. Thank you. You may begin.
Good afternoon. Thank you for joining us today for CVRX's second quarter 2026 earnings conference call. Join me on today's call are the company's President and Chief Executive Officer, Kevin Hykes, and Chief Financial Officer, Jared Oasheim.
Remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings.
I would now like to turn the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
